Cell-Based Biosensor for Alzheimer's Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for early diagnosis of Alzheimer's disease are ineffective due to the challenge of detecting small quantities of pathogenic amyloid-β (Aβ) oligomers in the presence of larger quantities of inert Aβ monomers, and existing tests do not specifically detect pathogenic forms of Aβ, leading to late-stage detection of brain changes.
Innovation Solution
A cell-based biosensor using a monolayer of brain microvascular endothelial cells measures transendothelial electrical resistance (TEER) to detect pathogenic Aβ aggregates, with a decrease in TEER indicating the presence of Aβ oligomers, and amplification of low concentrations using synthetic monomers to enhance detection sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional biochemical measurements are used to detect Aβ, then the measurement process is simple, but the detection precision is insufficient due to inability to distinguish pathogenic oligomers from inert monomers
Solution Approach 1:
The patent uses an intermediary substance (synthetic Aβ monomer) that selectively binds to pathogenic Aβ oligomers in the sample, forming detectable complexes. This intermediary enables specific detection of oligomers without directly measuring them, resolving the contradiction between detection precision and device complexity by adding a simple chemical mediator rather than a complex analytical system
Solution Approach 2:
The patent replaces complex mechanical or instrumental detection systems with a biochemical assay approach using synthetic monomers and readout methods. This substitution achieves high detection precision through chemical specificity rather than through complex physical measurement devices
2Measurement precision
If current blood tests measuring total Aβ are used, then the testing procedure is straightforward, but the measurement precision is insufficient because they cannot specifically detect pathogenic forms of Aβ
Solution Approach 1:
The synthetic Aβ monomer acts as a selective intermediary that binds only to pathogenic oligomers, enabling specific detection while maintaining operational simplicity. The assay procedure remains straightforward like current blood tests, but gains specificity through the selective binding properties of the intermediary substance
Solution Approach 2:
The patent changes the detection parameter from measuring total Aβ concentration to measuring the specific interaction between synthetic monomers and pathogenic oligomers. This parameter change enables discrimination between pathogenic and non-pathogenic forms while maintaining ease of operation through standardized assay procedures
3Loss of time
If MRI or PET scans are used to detect brain changes, then the detection method is reliable for advanced stages, but the detection timing is too late as changes occur only at late stages of the disease
Solution Approach 1:
The patent performs preliminary detection of Aβ oligomers in blood or CSF samples before significant brain damage occurs. By detecting the presence of pathogenic oligomers early in the disease process, the system enables early intervention before the irreversible neuronal death that characterizes late-stage Alzheimer's, thus reducing the time loss without sacrificing detection precision
Solution Approach 2:
The patent uses synthetic Aβ monomers as copies or analogs of the natural pathogenic oligomers. These synthetic copies bind specifically to the pathogenic forms in patient samples, enabling detection of early disease markers with high precision through a simplified in vitro assay rather than requiring complex neuroimaging
4Measurement precision
If amplification using synthetic monomers is applied to low concentrations of Aβ oligomers, then the detection sensitivity increases, but the device complexity increases due to additional amplification steps
Solution Approach 1:
The synthetic Aβ monomer serves as an amplifying intermediary that binds to low-concentration pathogenic oligomers, effectively amplifying the signal. Each oligomer molecule can bind multiple synthetic monomers or facilitate detectable complex formation, increasing detection sensitivity without requiring complex amplification machinery or multiple processing steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for early detection of Alzheimer's disease by selectively identifying pathogenic Aβ oligomers, even in the presence of inert monomers, providing a cost-effective and sensitive diagnostic tool for early-stage disease detection.
Implementation Method 1
measuring transendothelial electrical resistance in a monolayer of brain microvascular endothelial cells
Implementation Method 2
a decrease in transendothelial electrical resistance is indicative of Alzheimer's disease... a decrease in transendothelial electrical resistance may be indicative of the presence of at least one pathogenic Aβ aggregate
Implementation Method 3
a synthetic monomer may be used to amplify a concentration of at least one physiologically active Aβ aggregate to increase compromise of the monolayer of brain microvascular endothelial cells
Data Source
AI summary
The present disclosure has identified a unique cellular response to the pathogenic form of the amyloid-ß protein (Aß) and will employ a cell-based biosensor to leverage this response for early detection of Alzheimer's disease (AD) by determining if the pathogenic form of Aß is present in the cerebral spinal fluid or blood of a patient.